Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Sanofi

Genzyme sales up 17% in the quarter to $1.5 billion; completes acquisition of Boehringer CHC business

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi
4Q Revenues: €8.7 billion (-2%)
4Q Earnings: €159 million (-80%)
FY Revenues:  €35.1 billion (+4%)
FY Earnings: €8.6 billion (+78%)
Comments: Pharmaceutical sales were up 3% in the quarter to €7.3 billion. Rare Disease sales increased 8% to €726 million. Genzyme sales were up 17% to $1.5 billion driven by contribution from new immunology franchise. Myozyme/ Lumizyme sales were $205 million in the quarter, up 12%. Cerezyme and Cerdelga sales were up 9% to €216 million supported by additional launches. Multiple Sclerosis sales grew 11% to €501 million, driven by Aubagio with sales up 14% to €389 million. Lemtrada sales were up 1% to €112 million. Oncology sales increased 4% in the quarter to €361 million. Diabetes sales decreased 16% to €1.5 billion, due to lower Sanofi glargine (Lantus and Toujeo) sales, reflecting exclusions from commercial formularies at CVS and UnitedHealthcare. Consumer Healthcare sales increased 52% to €1.2 billion reflecting the acquisition of Boehringer Ingelheim CHC business. Vaccines sales were up 9% to €1.4 billion and reflected the termination of the Sanofi Pasteur MSD joint venture in Europe. Sanofi Pasteur sales increased 1% impacted by order phasing effects and Dengvaxia. Results in the quarter reflect the acquisition Boehringer Ingelheim CHC business and the disposal of the Animal Health business.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters